Retatrutide (LY3437943): Molecular Characterization and Receptor Pharmacology — A Research Reference

Retatrutide is a 39-amino-acid peptide analogue built on a GIP-derived backbone, incorporating non-natural amino acid substitutions — including α-aminoisobutyric acid (Aib) residues — that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 and shape its receptor-activity profile [1]. A C20 fatty diacid moiety is conjugated to a lysine residue via a hydrophilic linker; this lipidation promotes reversible albumin binding, which extends the peptide's circulating stability — a protein-engineering strategy shared with other acylated peptide analogues in the research literature [1, 2].

What distinguishes retatrutide structurally is that all three receptor activities are engineered into a single peptide chain — a "unimolecular polyagonist" — rather than achieved by co-administering separate ligands. Unimolecular multi-receptor design has been an active area of peptide-engineering research for over a decade [3], because a single molecule guarantees a fixed ratio of receptor activities at any concentration, which co-administered mixtures cannot.

In published receptor-pharmacology characterization, retatrutide functions as an agonist at GIPR, GLP-1R, and GCGR — all class B secretin-family GPCRs that couple principally to Gαs, stimulating adenylyl cyclase and raising intracellular cyclic AMP upon activation [1, 4, 5]. Its engineered potency is deliberately imbalanced relative to the native hormones: in-vitro characterization describes greater relative potency at GIPR, with attenuated-but-meaningful activity at GLP-1R and GCGR compared with each receptor's endogenous ligand [1]. Ratio-tuning of this kind is a central design question in polyagonist research — the relative activity at each receptor, not merely the presence of activity, defines the molecule's pharmacological character.

The Three Target Receptors

GIPR is the receptor for glucose-dependent insulinotropic polypeptide, a 42-amino-acid incretin hormone secreted by intestinal K-cells. GIPR is expressed in pancreatic islets, adipose tissue, and the central nervous system, and signals predominantly through Gαs/cAMP [4, 5].

GLP-1R is the receptor for glucagon-like peptide-1, a proglucagon-derived incretin secreted by intestinal L-cells. It is among the most extensively characterized class B GPCRs, with published cryo-EM structures of ligand-bound states, and is expressed in pancreatic islets, the gastrointestinal tract, heart, and brain [4, 6].

GCGR is the receptor for glucagon, the 29-amino-acid proglucagon-derived hormone of pancreatic α-cells, expressed most abundantly in liver [7]. Engineering agonism at GCGR alongside incretin-receptor agonism — rather than in isolation — is the defining pharmacological question that unimolecular triple agonists like retatrutide were designed to study [1, 3, 7].

For receptor-pharmacology researchers, retatrutide is therefore a working example of three engineering problems solved in one molecule: protease-resistant backbone design, lipidation-based half-life extension, and multi-receptor potency tuning.

Retatrutide's structural complexity has direct consequences for quality verification. A 39-residue engineered analogue with non-natural residues and a lipid conjugate presents more opportunities for synthesis-related impurities — truncated sequences, deletion variants, oxidation products, and incomplete conjugation — than simple short peptides. Standard analytical characterization comprises:

• Reversed-phase HPLC for purity assessment and impurity profiling;
• Mass spectrometry for identity confirmation against the theoretical molecular mass;
• Batch-specific documentation tying both analyses to the specific production lot.

For research applications, material without batch-specific third-party analytical documentation is effectively uncharacterized — the identity and purity of the specific lot cannot be assumed from a generic specification sheet. A batch-specific certificate of analysis (COA) reporting independent HPLC and mass-spectrometry results is the minimum documentation standard a laboratory should require. Researchers evaluating suppliers can review the batch documentation and specifications published for research-grade retatrutide as a reference for what transparent analytical documentation should include.

Research-grade retatrutide is supplied as a lyophilized powder. General peptide-chemistry principles apply:

• Lyophilized form: stable when stored cold, desiccated, and protected from light. Repeated exposure to ambient humidity degrades lyophilized peptides over time.
• Reconstituted solutions: reconstituted peptide solutions have a substantially shorter usable window than lyophilized material and require refrigeration; repeated freeze–thaw cycles should be avoided.
• Lipidated analogues: the fatty-diacid conjugate makes solubility and solution behavior somewhat distinct from unmodified peptides; gentle swirling rather than vigorous agitation is standard practice to avoid foaming and interfacial denaturation.

Retatrutide is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Retatrutide (LY3437943) is a lipidated, protease-resistant, 39-amino-acid unimolecular agonist of GIPR, GLP-1R, and GCGR — a single molecule embodying the current state of multi-receptor peptide engineering [1, 3]. For the laboratory, its structural complexity makes analytical verification non-negotiable: batch-specific, third-party HPLC and mass-spectrometry documentation is the baseline standard for meaningful research use.